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Apart from apoptotic bodies and ecto-
somes, microvesicles that bud out of the
plasma membrane, most types of cells
release exosomes when intracellular endo-
somal microvesicular bodies fuse with their
plasma membrane. This last type of vesicles
with attributed intercellular communicat-
ing capabilities has acquired an enormous
attention in the past two decades, especially
for their potential as disease biomarkers
and/or their use as therapeutic vehicles.
The intense study of their molecular com-
position with special attention to miRNA
has led to the development of databases
like Exocarta (http://www.exocarta.org/)
(1); however, the way exosomes released
from tumors (Tex) that may influence can-
cer patient’s health is not yet completely
understood.
The observation that exosome pro-
duction and release is notably increased
with tumor progression suggests that they
must play an active role in cancer (2,
3). As tumors become more aggressive,
heparanase activity is enhanced at least
in myeloma, lymphomas, or breast cancer,
increasing both the number of exosomes
released and the amount of syndecan-1,
VEGF, and HGF molecules exposed on
their surface (4).
The advantages that Tex present for the
delivery of tumorigenic signaling mole-
cules in relation to passive release into the
medium are clear, especially for transports
across long distances in the body. Firstly,
encapsulation of labile molecules such as
RNAs and proteins within lipid bilayers
offers them protection to degradation; sec-
ondly, the surface landscape of the vesicle
allows for the possibility of tissue or cell
specific targeting and thirdly they are suited
for simultaneous multiple message delivery
allowing horizontal transfer of complex
information from cancer to healthy cells.
In addition to attenuation of antitu-
mor immunity, Tex stimulate angiogen-
esis, modulate stromal cells activity, and
help on the extracellular matrix remod-
eling contributing to the establishment
of a premetastatic niche and generat-
ing suitable microenvironments at distant
metastatic sites (5). For example, Tex from
glioblastoma have the ability to potentiate
tumor growth (6) and Tex from melanoma
can directly tune a remote lymph node
into a microenvironment that facilitates
melanoma growth and metastasis even in
the local absence of tumor cells (7). These
and other similar studies suggest that Tex
activities are mediated, at least in part,
through the action of particular miRNAs,
which presumably down regulate their tar-
get transcripts in recipient cells (8, 9). Inter-
estingly enough, Fabbri et al. have recently
showed that the Tex miR-21 and 29a mol-
ecules can bind to toll-like receptor 7 and
8 (TLR7 and 8) on immune cells and acti-
vate them, leading to TLR-mediated NF-
kB activation and secretion of prometasta-
tic inflammatory cytokines (10, 11). This
offers an alternative mode of action for
the miR-mediated Tex paracrine effects in
which miR act as aptamer-ligands. So, in
addition to Tex internalization Tex pro-
tein, lipid, carbohydrate, or nucleic acid
surface receptors could interact with target
cell receptors to activate intracellular sig-
naling; or, their surface proteins could be
cleaved by proteases, and the correspond-
ing soluble fragments act as soluble lig-
ands binding to target cell surface receptors
(12). In one case or another, Tex-mediated
activities are a threat to patients working
toward disease progression. Importantly,
anti-cancer agents directed to inhibit DNA
replication or microtubule dynamics will
result innocuous to Tex. This is, Tex present
themselves, together with cancer stem cells,
as a therapeutic resistant reservoir for the
advancement of the disease, and therefore
effective cancer treatments must include
targeted inactivation and/or removal of
Tex.
On another side, however, exosomes
have emerged as potent stimulators of
immune responses and from this point
of view as agents for cancer therapy.
It has been recently showed that induc-
tion of HSPs (heat shock proteins)-loaded
Tex occurred when hepatocarcinoma cells
were treated with chemotherapeutics such
as paclitaxel or carboplatin. These Tex
released by treated cancer cells con-
ferred superior immunogenicity in induc-
ing HSPs-specific NK cell responses (13).
Exosomes can carry a broad variety of
immune-stimulatory molecules depending
on the cell of origin and in vitro cul-
ture conditions. In particular, dendritic
cell (DC)-derived exosomes (dexosomes)
have been shown to carry NK cell acti-
vating ligands and can be loaded with
antigens to activate invariant NKT cells
to induce antigen-specific T and B cell
responses. Tumor-antigen-derived dexo-
somes have been investigated as thera-
peutic agents against cancer in two phase
I clinical trials, with a phase II clinical
trial currently ongoing. The results show
that although dexosomes were well toler-
ated, the therapeutic success and immune
activation were limited (14, 15). Multi-
ple factors need to be considered in order
to improve exosomal immunogenicity for
cancer immunotherapy. For example, Tex
immunostimulatory effect has been shown
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to depend on host’s DCs while dexosomes
do not (16). Because of their abundant
expression of tumor antigens, Tex can be
envisaged as an acellular source of anti-
genic determinants to be exploited in the
production of cancer-vaccines and there-
fore as a therapeutic cancer agent by itself
or as a co-adjuvant treatment (17).
Although immune cells, and probably
dexosomes, can be found in primary tumor
lesions as infiltrating components playing
favorable prognostic role (18), in metasta-
tic lesions anti-cancer activities are sup-
pressed due to Tex derived immunosup-
pressive effects allowing tumor progres-
sion. One of the mechanisms responsible
for this undesired effect in different types of
solid cancers uses endocytic FasL and also
TRAIL loaded pro-apoptotic Tex to elim-
inate overreactive Fas-expressing T cells
(19). Thus, Tex in malignant ascites effu-
sions and other cancer patient fluids can
eliminate activated T cells through a simple
ligand–receptor interaction. In addition,
functional CD39 and CD73 Tex are capa-
ble of dephosphorylating ATP and AMP
to form adenosine to negatively regulate
local immune responses (20). Tex can also
inhibit DC differentiation, inhibit T-cell
proliferation through TGF-β interactions,
and promote tumor-immune evasion by
interfering with NK cells (19) eventually
hijacking the anti-cancer immune response
that they might have initiated.
Reached this point, the key question for
cancer therapeutics is: will patients benefit
by the presence of Tex or effective removal
of Tex should be recommended?
The answer does not seem to be straight
forward but recent modeling for puta-
tive therapeutic implications of exosome
exchange between tumor and immune cells
may throw some light on it (21). The
authors propose the existence of three can-
cer states: a low cancer load (L) with inter-
mediate immune-level state, and interme-
diate cancer load (I) with high immune-
level state and a high cancer load (H)
with low immune-level state. To design
and assess possible therapeutic protocols,
the authors built a cancer-immunity land-
scape that includes dynamical states of the
cancer-immunity interplay allowing for the
visualization of combined protocols as tra-
jectories connecting different states. For
example, when the immune recognition
is low, the effect of the immune system
will not be strong enough to limit cancer
progression.
An important observation that should
be included in Lu et al. model is that exo-
some release is controlled by feedback reg-
ulatory loops that involve not only cancer
cells but also exosome production by nor-
mal cells. In this sense, it has been reported
that exosome release from normal human
mammary epithelial cells and breast cancer
cells is not only regulated by the presence
of exosomes derived from their own cells
but also exosomes from normal mammary
epithelial cells inhibit exosome secretion
by breast cancer cells in a tissue specific
manner, implicating a dynamic equilib-
rium between exosome release of normal
and tumor cells (22).
It is of relevance as well to point out
that the different cancer-load-states may
refer not only to quantitative traits but
also to qualitative cancer-associated fea-
tures. For example, cancer-specific mem-
brane bound isoforms such as EGFRvIII,
generated by defective alternative splicing
mechanisms, have been detected on the
surface of Tex (6). Such distinctive cancer-
associated exons could be used for the
design of directional therapeutics, allow-
ing selective inactivation or sequestration
of Tex with minimal interference of nor-
mal cell exosome activity, reducing possible
secondary effects. In addition to antibody-
based strategies, synthetic peptides and
nucleic acid aptamers have proven not only
to bind specifically and tightly to can-
cer cells but also to home to cancer cells
in vivo (23–25). Similar approaches could
be used to block or sequester Tex through
their particular surface landscapes. Target-
ing through common receptors such as
tetraspanins could interfere with normal
exosome functions and therefore is not
recommended.
The fact that solid tumors are het-
erogeneous in nature adds yet another
degree of complexity to cancer therapeu-
tics. Tumor heterogeneity will be reflected
into a multivariety of Tex. Taking into
account that the current methods for Tex
isolation are based on vesicle size, density,
and enrichment of certain common mark-
ers (tetraspanins) (26), we can conclude
that Tex fractions are far from pure. A pos-
sible strategy to study more homogeneous
Tex populations would be to establish cell
lines from microdissected biopsies so that
enough Tex of a particular type can be pro-
duced and isolated. This should allow for
a better characterization of the Tex com-
plex landscapes, some of them dependent
on cancer-associated splicing switches.
Deregulation of splicing is associated to
acquisition of cancer advantages, aggres-
siveness of the tumor, and drug resistance
events (27–29). For example, the inclusion
of an exon in the pyruvate kinase tran-
script allows for activation of glycolytic
pathway of cancer cells (Warburg’s effect),
and the KLF6-SV1 variant is associated
with poor prognosis and tumor aggressive-
ness in prostate, lung, and ovarian can-
cers, associated to EMT (epithelial to mes-
enchymal transition) (30). In the context
of directional targeting of Tex, it would
be important to identify specific cancer-
associated exons located on the external
side of the vesicles. They may or may
not be present in the plasmatic membrane
of the tumor cell of origin. Toward this
end, strategies such as screening of ran-
dom libraries based on phage display and
SELEX (Systematic Evolution of Ligands
by EXponential enrichment) technologies
allow for the identification of synthetic
peptides and aptamers without previous
knowledge of the altered splicing events
(31, 32). Perhaps, tumor therapies sup-
pressing the splicing machinery itself are
advantageous to current systemic cancer
treatments.
Tex cancer-associated exon sequences
could be used for immunotherapy, to
boost DC dexosome release and, at the
same time, as targets for Tex inactiva-
tion and/or sequestration. If only inacti-
vation/sequestration is applied, the patient
would miss the benefit of the immune
response against the tumor. On the
other side, if the unloading of Tex is
not prevented, their cargo will work
toward advancement of the disease. This
double-approach consisting on blocking
Tex function while using their specific
cancer-associated exon sequences to induce
tumor-immune response could comple-
ment current tumor treatments to reduce
relapses and to limit metastatic events
in immuno-competent patients. In addi-
tion, this directional targeting strategy
would leave exosome-dependent physio-
logical functions unaffected.
In summary, the study of Tex sur-
face landscape and the detection of
Frontiers in Endocrinology | Cancer Endocrinology November 2014 | Volume 5 | Article 194 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oltra Exosome landscapes in cancer therapeutics
cancer-specific exons on Tex derived from
alternative splicing events results essential
for the development of Tex targeted ther-
apies. These qualitative switches should
be considered in the context of patient
immunological and cancer load states for
the modeling and the development of
improved, personalized cancer therapeutic
programs.
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